Brought to you by 
Neuromodulation company electroCore completes $40mm Series A financing; adds $10mm
01 Jul 2014
Executive Summary
ElectroCore LLC, which is targeting nerve signal imbalances via neuromodulation, completed a $40mm Series A financing from Merck Global Health Innovation LLC (operated by Merck & Co. Inc.) and private equity firms Easton Capital and Core Ventures II.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neuromodulation company electroCore completes $40mm Series A financing; adds $10mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice